Fresh from leading Cathay Capital's healthcare division, Hongjie Hu has joined Novo's investment arm as a growth-stage partner.
Novo Holdings, the investment arm of Danish pharmaceutical group Novo, has hired Hongjie Hu as a partner.
Hu will focus on growth investments, working out of Novo Holdings’ San Francisco office. He had previously spent over four years as managing partner at investment firm Cathay Capital, where he founded and led healthcare division Cathay Health.
Novo Holdings is one of the most active investors in healthcare startups worldwide, participating from seed to private equity stage. It has led nine-figure rounds for circulatory support device developer Suspira Bio and pharmaceutical startups Windward Bio and GlycoEra already this year.
Hu began his career in engineering before taking on associate roles at venture firm Crosslink Capital and private equity firms HIG Capital and Bain Capital in the 2000’s. That led to a decade-long stint at Singaporean state-owned investment firm Temasek, where he focused on agricultural technology and then healthcare.
